Bristol Myers Squibb Company $BMY Shares Sold by Prospera Financial Services Inc

Prospera Financial Services Inc cut its position in shares of Bristol Myers Squibb Company (NYSE:BMY) by 21.6% during the 3rd quarter, according to the company in its most recent filing with the SEC. The firm owned 42,330 shares of the biopharmaceutical company’s stock after selling 11,667 shares during the quarter. Prospera Financial Services Inc’s holdings in Bristol Myers Squibb were worth $1,910,000 as of its most recent filing with the SEC.

Other institutional investors have also modified their holdings of the company. Darwin Wealth Management LLC bought a new stake in Bristol Myers Squibb in the second quarter worth about $25,000. Harbor Capital Advisors Inc. raised its holdings in shares of Bristol Myers Squibb by 107.2% in the 3rd quarter. Harbor Capital Advisors Inc. now owns 605 shares of the biopharmaceutical company’s stock worth $27,000 after purchasing an additional 313 shares in the last quarter. Total Investment Management Inc. acquired a new stake in Bristol Myers Squibb during the second quarter valued at approximately $38,000. Twin Peaks Wealth Advisors LLC bought a new stake in Bristol Myers Squibb during the second quarter worth approximately $40,000. Finally, Mark Sheptoff Financial Planning LLC grew its position in Bristol Myers Squibb by 233.3% in the second quarter. Mark Sheptoff Financial Planning LLC now owns 1,000 shares of the biopharmaceutical company’s stock worth $46,000 after buying an additional 700 shares during the last quarter. Institutional investors and hedge funds own 76.41% of the company’s stock.

Bristol Myers Squibb Stock Performance

NYSE BMY opened at $60.64 on Friday. The firm has a market cap of $123.49 billion, a price-to-earnings ratio of 17.58, a PEG ratio of 0.17 and a beta of 0.29. Bristol Myers Squibb Company has a 1-year low of $42.52 and a 1-year high of $63.33. The company has a 50 day moving average of $55.33 and a 200-day moving average of $49.44. The company has a current ratio of 1.26, a quick ratio of 1.17 and a debt-to-equity ratio of 2.32.

Bristol Myers Squibb (NYSE:BMY) last issued its quarterly earnings data on Thursday, February 5th. The biopharmaceutical company reported $1.26 earnings per share (EPS) for the quarter, missing the consensus estimate of $1.65 by ($0.39). The business had revenue of $12.50 billion during the quarter, compared to the consensus estimate of $12.24 billion. Bristol Myers Squibb had a net margin of 14.64% and a return on equity of 69.65%. The company’s revenue for the quarter was up 1.3% compared to the same quarter last year. During the same quarter in the previous year, the firm posted $1.67 EPS. Bristol Myers Squibb has set its FY 2026 guidance at 6.050-6.350 EPS. On average, equities analysts forecast that Bristol Myers Squibb Company will post 6.74 earnings per share for the current fiscal year.

Bristol Myers Squibb Increases Dividend

The business also recently disclosed a quarterly dividend, which was paid on Monday, February 2nd. Shareholders of record on Friday, January 2nd were issued a dividend of $0.63 per share. The ex-dividend date of this dividend was Friday, January 2nd. This represents a $2.52 dividend on an annualized basis and a yield of 4.2%. This is an increase from Bristol Myers Squibb’s previous quarterly dividend of $0.62. Bristol Myers Squibb’s payout ratio is currently 73.04%.

Wall Street Analyst Weigh In

Several research analysts have recently weighed in on BMY shares. Citigroup lifted their target price on shares of Bristol Myers Squibb from $60.00 to $64.00 and gave the stock a “neutral” rating in a research report on Friday, February 6th. Guggenheim restated a “buy” rating and set a $72.00 price target (up previously from $62.00) on shares of Bristol Myers Squibb in a report on Friday, February 6th. UBS Group upgraded Bristol Myers Squibb from a “neutral” rating to a “buy” rating and boosted their target price for the stock from $46.00 to $65.00 in a report on Wednesday, January 7th. Wall Street Zen upgraded shares of Bristol Myers Squibb from a “buy” rating to a “strong-buy” rating in a report on Saturday, November 8th. Finally, Piper Sandler restated an “overweight” rating and issued a $66.00 price objective (up previously from $62.00) on shares of Bristol Myers Squibb in a research note on Wednesday, January 28th. Eight research analysts have rated the stock with a Buy rating, eleven have given a Hold rating and one has issued a Sell rating to the company. According to MarketBeat.com, the stock presently has an average rating of “Hold” and a consensus price target of $59.20.

Bristol Myers Squibb Profile

Bristol Myers Squibb is a global biopharmaceutical company headquartered in Princeton, New Jersey, focused on discovering, developing and delivering medicines for serious diseases. The company’s core activities include research and development, clinical development, manufacturing and commercialization of prescription pharmaceuticals across multiple therapeutic areas. BMS concentrates on advancing therapies in oncology, hematology, immunology, cardiovascular disease and specialty areas through both small molecules and biologics.

BMS’s marketed portfolio and late‑stage pipeline reflect a strong emphasis on cancer and immune‑mediated conditions.